Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PYGL | P06737 | 11/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879640 | 0.81 | PYGL (0.62) | KDM4EALDH1A1HPGDPYGL | |
| SCHEMBL13879604 | 0.80 | CYP3A4 (0.69) | KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL13879634 | 0.78 | RAB9A (0.73) | KDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL13879643 | 0.73 | ITGB2 (0.68) | ALDH1A1LMNAPYGL | |
| SCHEMBL8847705 | 0.73 | ALDH1A1 (0.72) | KDM4EALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL17219685 | 0.72 | ALDH1A1 (0.70) | KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL15854248 | 0.72 | ALDH1A1 (0.70) | KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL27885159 | 0.72 | ALDH1A1 (0.69) | KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL4409431 | 0.71 | KDM4E (0.80) | KDM4EALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL17219490 | 0.70 | SMN1; SMN2 (0.84) | KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | KDM4E 797/4885ALDH1A1 1500/4885SMN1; SMN2 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.